keyword
MENU ▼
Read by QxMD icon Read
search

Chronic spontaneous urticaria

keyword
https://www.readbyqxmd.com/read/28924988/benefit-from-reslizumab-treatment-in-a-patient-with-chronic-spontaneous-urticaria-and-cold-urticaria
#1
Marcus Maurer, Sabine Altrichter, Martin Metz, Torsten Zuberbier, Martin K Church, Karl-Christian Bergmann
Chronic urticaria (CU) is a group of common and debilitating conditions containing both chronic spontaneous urticaria (CSU) and chronic inducible urticarias (CIndU) including cold urticaria (ColdU) [1]. While antihistamines and omalizumab are effective treatments for both CSU and ColdU [2], many patients show insufficient response to either or both of these treatments [3], and additional and better therapies are needed [4]. This article is protected by copyright. All rights reserved.
September 19, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28916431/cyclosporine-for-chronic-spontaneous-urticaria-a-meta-analysis-and-systematic-review
#2
Kanokvalai Kulthanan, Pichanee Chaweekulrat, Chulaluk Komoltri, Saowalak Hunnangkul, Papapit Tuchinda, Leena Chularojanamontri, Marcus Maurer
BACKGROUND: Despite widely recommended usage of cyclosporine A (CsA) in chronic spontaneous urticaria (CSU), there is no meta-analysis concerning its efficacy and safety. OBJECTIVE: To meta-analyze and review the efficacy and safety of CsA in CSU. METHODS: Efficacy was assessed by the relative change in urticaria activity score at 4 weeks and response rates at 4, 8, and 12 weeks. Safety was assessed by analyzing the number of patients with 1 or more adverse event...
September 12, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28913986/chronic-spontaneous-urticaria-pathogenesis-and-treatment-considerations
#3
REVIEW
Allen P Kaplan
The treatment of chronic spontaneous urticaria begins with antihistamines; however, the dose required typically exceeds that recommended for allergic rhinitis. Second-generation, relatively non-sedating H₁-receptor blockers are typically employed up to 4 times a day. First-generation antihistamines, such as hydroxyzine or diphenhydramine (Atarax or Benadryl), were employed similarly in the past. Should high-dose antihistamines fail to control symptoms (at least 50%), omalizumab at 300 mg/month is the next step...
November 2017: Allergy, Asthma & Immunology Research
https://www.readbyqxmd.com/read/28898460/burden-of-chronic-urticaria-relative-to-psoriasis-in-five-european-countries
#4
M M Balp, S Khalil, H Tian, S Gabriel, J Vietri, T Zuberbier
BACKGROUND: Quantification of burden of chronic spontaneous urticaria (CSU) versus psoriasis (PsO) is limited. OBJECTIVE: To evaluate the burden associated with CSU versus PsO of all severities (overall PsO), mild and moderate/severe PsO. METHODS: his retrospective cross-sectional analysis compared data from adult patients with chronic urticaria (CU), used as a proxy for CSU, and PsO from the National Health and Wellness Survey in France, Germany, Italy, Spain, and the United Kingdom...
September 12, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28884989/hydroxychloroquine-in-the-treatment-of-anti-histamine-refractory-chronic-spontaneous-urticaria-randomized-single-blinded-placebo-controlled-trial-and-an-open-label-comparison-study
#5
T Boonpiyathad, A Sangasapaviliya
Background. The management of anti-histamine refractory chronic spontaneous urticaria (CSU) has poorly defined therapeutic options. Some patients with CSU respond poorly to a fourfold increase in dosage of H1-anti-histamines treatment. Aim. The objective of this study was to determine the effect of an adjunct treatment of hydroxychloroquine (HCQ) on remission rate and reduction of urticarial symptoms. Methods. Sixty subjects with anti-histamine refractory CSU were randomly assigned to 400 mg of HCQ daily or placebo for 12 weeks in a single blind placebo controlled trial...
September 2017: European Annals of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28884987/the-link-between-chronic-spontaneous-urticaria-and-metabolic-syndrome
#6
G A Vena, N Cassano
Metabolic syndrome (MS) is a cluster of risk factors for cardiovascular disease and is considered a chronic low-level systemic inflammatory condition. Recent preliminary findings have shown an increased prevalence of MS among patients with chronic urticaria (CU) as compared to controls, with a particularly higher prevalence detected in patients with uncontrolled CU. Chronic spontaneous urticaria (CSU) appears to share some pathomechanisms with MS, including a pro-inflammatory state, increased oxidative stress, alterations in adipokine profile and activation of the coagulation system...
September 2017: European Annals of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28871952/-up-regulated-expression-of-nk1r-in-eosinophil-enriched-blood-cells-from-patients-with-chronic-spontaneous-urticaria
#7
Wei Wang, Huiyun Zhang, Wenjiao Zheng, Shaoheng He
Objective To investigate the expressions of substance P (SP) and neurokinin-1 receptor (NK1R) in eosinophil-enriched blood cells from patients with chronic spontaneous urticaria (CSU). Methods Peripheral venous blood samples were collected from patients with CSU and healthy controls (HCs), and then stimulated with crude extracts of Artemisia pollen, dust mite, and Platanus pollen (all at concentrations of 0.1 and 1.0 μg/mL). The expressions of SP and NK1R in eosinophil-enriched blood cells were detected by flow cytometry...
August 2017: Xi Bao Yu Fen Zi Mian Yi Xue za Zhi, Chinese Journal of Cellular and Molecular Immunology
https://www.readbyqxmd.com/read/28870460/elevated-ige-levels-are-linked-to-faster-relapse-in-omalizumab-discontinued-chronic-spontaneous-urticaria-patients
#8
Ragip Ertas, Kemal Ozyurt, Emin Ozlu, Yilmaz Ulas, Atil Avci, Mustafa Atasoy, Tomasz Hawro, Marcus Maurer
No abstract text is available yet for this article.
September 1, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28852410/management-of-chronic-spontaneous-urticaria-csu-a-treat-to-target-approach-using-a-patient-reported-outcome
#9
Hermenio Lima, Melinda Gooderham, Jan Dutz, Charles Lynde, Hugo Chapdelaine, Anne Ellis, Martin Gilbert, Vincent Ho, Kim Papp, Yves Poulin, Gordon Sussman
BACKGROUND: Treat-to-target therapy approaches are established for chronic diseases such as diabetes, hypertension, and more recently rheumatoid arthritis, resulting in improved patient outcomes. These approaches do not use patient reported outcomes (PRO) as targets of therapy. Chronic spontaneous urticaria (CSU), also called chronic idiopathic urticaria (CIU), is defined as recurrent urticaria of known and unknown cause, lasting more than 6 weeks. Treatment of CSU can be challenging...
2017: Allergy, Asthma, and Clinical Immunology
https://www.readbyqxmd.com/read/28846158/different-expression-patterns-of-plasma-th1-th2-th17-and-th22-related-cytokines-correlate-with-serum-autoreactivity-and-allergen-sensitivity-in-chronic-spontaneous-urticaria
#10
Qiquan Chen, Hua Zhong, WenChieh Chen, Zhifang Zhai, Zhou Zhou, Zhiqiang Song, Fei Hao
BACKGROUND: Clinical features and basophil activation levels correlate with serum autoreactivity and allergen sensitivity in patients with chronic spontaneous urticaria (CSU). OBJECTIVES: To explore the relationship of the expression patterns of plasma T-helper cell (Th) 1, Th2, Th17, and Th22-related cytokines with the serum autoreactivity and the allergen sensitivity in CSU. METHOD: Twenty related cytokines were measured and analysed in 60 CSU patients, 15 acute urticaria patients, 10 patients with atopic dermatitis (AD), and 15 healthy persons, respectively...
August 28, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28827590/omalizumab-efficacy-in-cases-of-chronic-spontaneous-urticaria-is-not-explained-by-the-inhibition-of-sera-activity-in-effector-cells
#11
Eva Serrano-Candelas, Rubén Martínez-Aranguren, Olga Vega, Gabriel Gastaminza, Joan Bartra, Maria Teresa Audicana, Jorge M Núñez-Córdoba, Jaime Algorta, Antonio Valero, Margarita Martin, Marta Ferrer
Omalizumab (OmAb) is a humanized anti-IgE antibody approved for the treatment of chronic spontaneous urticaria (CSU). OmAb's mechanism of action is known to include actions on free IgE and on pre-bound IgE. However, OmAb is equally and rapidly effective against autoimmune and non-autoimmune urticaria where IgE involvement is not clear, suggesting the involvement of additional mechanisms of action. In this study, we sought to investigate the ability of OmAb to inhibit mast cell and basophil degranulation induced by sera from CSU patients...
August 21, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28819778/impact-of-jumihaidokuto-shi-wei-bai-du-tang-on-treatment-of-chronic-spontaneous-urticaria-a-randomized-controlled-study
#12
Hiroyuki Murota, Hiroaki Azukizawa, Ichiro Katayama
OBJECTIVE: To study the effect of Jumihaidokuto (Shi-Wei-Bai-Du-Tang, ) in the management of chronic spontaneous urticaria. METHODS: A randomized two-arm, parallel group study was conducted to compare the effect of Jumihaidokuto (6 g daily) with a control for 8 weeks. Concomitant therapy (e.g., antihistamines) was continued. Twenty-one subjects with severe chronic urticaria were enrolled in this study. The primary treatment outcome was the severity score proposed by the Japanese Dermatological Association...
August 17, 2017: Chinese Journal of Integrative Medicine
https://www.readbyqxmd.com/read/28815631/comparison-and-interpretability-of-the-available-urticaria-activity-scores
#13
T Hawro, T Ohanyan, N Schoepke, M Metz, A Peveling-Oberhag, P Staubach, M Maurer, K Weller
The urticaria activity score (UAS) is the gold standard for assessing disease activity in patients with chronic spontaneous urticaria (CSU). Two different versions, the UAS7 and UAS7TD , are currently used in clinical trials and routine care. To compare both versions and to obtain data on their interpretability, 130 CSU patients applied both versions and globally rated their disease activity as none, mild, moderate, or severe. UAS7 and UAS7TD values correlated strongly (r=0.90, P<0.001). Interquartile ranges for UAS7 and UAS7TD values for mild, moderate and severe CSU were 11-20 and 10-24, 16-30 and 16-32, and 27-37 and 28-40...
August 16, 2017: Allergy
https://www.readbyqxmd.com/read/28754324/histopathological-and-clinical-evaluation-of-chronic-spontaneous-urticaria-patients-with-neutrophilic-and-non-neutrophilic-cutaneous-infiltrate
#14
Cíntia Freitas Martins, Karina Lopes Morais, Pamela Figueroa, Natasha Favoretto Dias, Neusa Sakai Valente, Celina Wakisaba Maruta, Paulo Ricardo Criado
BACKGROUND: Chronic urticaria has an expressive prevalence in general population, especially in adults, and is defined by the presence of intermittent hives for six weeks or longer. Our study aims to characterize the histological patterns of chronic spontaneous urticaria, based on the inflammatory cell infiltrate, and correlate them to laboratory exams. METHODS: It was performed a retrospective analysis of laboratory, histopathology and direct immunofluorescence data of 93 patients with chronic urticaria...
July 25, 2017: Allergology International: Official Journal of the Japanese Society of Allergology
https://www.readbyqxmd.com/read/28752724/crp-d-dimer-fibrinogen-and-esr-as-predictive-markers-of-response-to-standard-doses-of-levocetirizine-in-patients-with-chronic-spontaneous-urticaria
#15
P Kolkhir, D Pogorelov, O Olisova
According to current guidelines, non-sedative H1-antihistamines (nsAH) are the first-line therapy of chronic spontaneous urticaria (CSU). But even up-dosed antihistamines (to four times the standard dose) produce symptom resolution in less than 50% of patients. Biomarkers that can predict the response to nsAH are still unknown. We carried out a prospective study and used discriminant analysis to evaluate the combination of D-dimer, fibrinogen, C-reactive protein and ESR values for predicting the outcome of treatment with levocetirizine in 84 CSU patients...
July 2017: European Annals of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28752720/effects-of-omalizumab-treatment-on-serum-cytokine-concentrations-of-atopic-patients-with-chronic-spontaneous-urticaria-a-preliminary-report
#16
A Sellitto, U De Fanis, A Balestrieri, A Savoia, C Astarita, C Romano
Omalizumab has recently obtained indication for chronic spontaneous urticaria both in the US and Europe. However, the mechanism of action of this drug has yet to be fully elucidated. Previous studies have shown elevations in cytokine serum levels in patients with chronic spontaneous urticaria, and it is not known whether omalizumab treatment may affect cytokine serum levels in this condition. Besides, a proportion of chronic spontaneous urticaria patients have concomitant atopy, which may be associated, at least in theory, with prevalence of serum Th2-type cytokines...
July 2017: European Annals of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28752718/histamine-release-positive-test-associates-with-disease-remission-in-chronic-spontaneous-urticaria-a-proof-of-concept-study
#17
A Berti, M R Yacoub, P Stahl Skov, S Falkencrone, L Casati, S Burastero, M G Sabbadini, G Colombo
Background. Histamine release (HR) test has previously been shown to predict the presence of endogenous histamine-releasing factors in chronic spontaneous urticaria (CSU). Objectives and methods. Twenty CSU patients unresponsive to antihistamine treatment were enrolled in order to evaluate the correlations between HR test results and demographic features, quality of life, disease activity, clinical course, and autologous serum and plasma skin tests (ASST and APST). Results. All patients with positive HR test (9/9, 100%) had a more severe disease activity at onset (urticaria activity score, UAS > 2) when compared to negative HR test patients (5/11; p = 0...
July 2017: European Annals of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28752717/justification-for-ige-as-a-therapeutic-target-in-chronic-spontaneous-urticaria
#18
M Sánchez-Borges, A Capriles-Hulet, F Caballero-Fonseca, L González-Aveledo
Monoclonal anti-IgE antibodies (omalizumab) are able to induce clinically significant benefits in patients with severe chronic spontaneous urticaria (CS). Those results led clinicians and investigators to reconsider a possible pathogenic role not previously supported for IgE and its receptors in this disease, and to investigate additional approaches for understanding its pathogenesis. IgE antibodies to unknown environmental allergens able to trigger chronic urticaria are not generally regarded as the etiologic factor for the disease...
July 2017: European Annals of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28751972/chronic-urticaria-a-focus-on-pathogenesis
#19
REVIEW
Riccardo Asero, Alberto Tedeschi, Angelo Valerio Marzano, Massimo Cugno
Chronic urticaria is a spontaneous or inducible group of diseases characterized by the occurrence of wheals (and, in about half of cases, angioedema) for more than 6 weeks. These are rather frequent conditions that may severely affect patients' quality of life and sometimes represent a challenge for doctors as well. The causes of chronic urticaria are still poorly defined, although there is growing evidence that different biologic systems including immunity, inflammation, and coagulation may take part in the pathomechanism eventually leading to mast cell and basophil degranulation and hence to wheal formation...
2017: F1000Research
https://www.readbyqxmd.com/read/28751232/omalizumab-treatment-in-chronic-inducible-urticaria-a-systematic-review-of-published-evidence
#20
Marcus Maurer, Martin Metz, Randolf Brehler, Uwe Hillen, Thilo Jakob, Vera Mahler, Claudia Pföhler, Petra Staubach, Regina Treudler, Bettina Wedi, Markus Magerl
BACKGROUND: Omalizumab, a recombinant anti-IgE antibody, effectively treats chronic spontaneous urticaria. Evidence is lacking in chronic inducible urticarias (CIndUs), which are frequently H1-antihistamine resistant. OBJECTIVE: We aimed to determine, from the current published literature, the strength of evidence for omalizumab efficacy and safety in the treatment of CIndUs. METHODS: We performed a PubMed® search to identify evidence on omalizumab use in the following nine CIndU subtypes: symptomatic dermographism, cold urticaria, delayed pressure urticaria, solar urticaria, heat urticaria, vibratory angioedema, cholinergic urticaria, contact urticaria and aquagenic urticaria...
July 24, 2017: Journal of Allergy and Clinical Immunology
keyword
keyword
21212
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"